Expand AMRX Menu
AMRX MENU

AMRX Latest Press Releases

-- August 10, 2026 --

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader Globe Newswire 8:00 AM

-- July 30, 2026 --

Amneal Reports Second Quarter 2026 Financial Results Globe Newswire 6:00 AM

-- July 23, 2026 --

Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm Business Wire 1:27 PM

-- July 17, 2026 --

Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations Globe Newswire 8:00 AM

-- July 9, 2026 --

Amneal to Report Second Quarter 2026 Results on July 30, 2026 Globe Newswire 4:05 PM

-- June 29, 2026 --

Zambon and Amneal Announce Positive CHMP Opinion for Hopledo (IPX203) for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations Globe Newswire 3:00 AM

-- June 10, 2026 --

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals PRNewswire 10:09 AM

-- June 5, 2026 --

Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT in Parkinson's Disease Globe Newswire 8:00 AM

-- June 4, 2026 --

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution Globe Newswire 8:00 AM

-- June 1, 2026 --

Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026 Globe Newswire 8:00 AM

-- May 7, 2026 --

Amneal Reports First Quarter 2026 Financial Results Globe Newswire 4:01 PM

-- April 22, 2026 --

Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader Business Wire 6:17 AM
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance Globe Newswire 6:00 AM

-- April 20, 2026 --

Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT for Parkinson's Disease, Including Over 3 More Hours of Daily "Good On" Time When Switching from RYTARY Globe Newswire 8:00 AM

-- April 14, 2026 --

Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S. Globe Newswire 8:00 AM

-- April 9, 2026 --

Amneal Launches Bimatoprost Ophthalmic Solution, 0.01% Globe Newswire 8:00 AM

-- April 7, 2026 --

Amneal to Report First Quarter 2026 Results on May 1, 2026 Globe Newswire 4:01 PM
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson's Awareness Month Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes